0000899243-17-024245.txt : 20171016 0000899243-17-024245.hdr.sgml : 20171016 20171016170345 ACCESSION NUMBER: 0000899243-17-024245 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171013 FILED AS OF DATE: 20171016 DATE AS OF CHANGE: 20171016 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cheung Wilson Wai-Shun CENTRAL INDEX KEY: 0001291656 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19825 FILM NUMBER: 171139289 MAIL ADDRESS: STREET 1: SCICLONE PHARMACEUTICALS, INC. STREET 2: 950 TOWER LANE, SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SCICLONE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000880771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943116852 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 BUSINESS PHONE: 650-358-3456 MAIL ADDRESS: STREET 1: 950 TOWER LANE STREET 2: SUITE 900 CITY: FOSTER CITY STATE: CA ZIP: 94404-2125 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-10-13 1 0000880771 SCICLONE PHARMACEUTICALS INC SCLN 0001291656 Cheung Wilson Wai-Shun 950 TOWER LANE, SUITE 900 FOSTER CITY CA 94404 0 1 0 0 CFO & Senior VP, Finance Common Stock 2017-10-13 4 M 0 52000 A 69158 D Common Stock 2017-10-13 4 A 0 75000 0.00 A 144158 D Common Stock 2017-10-13 4 D 0 144158 11.18 D 0 D Non-Qualified Stock Option (right to buy) 5.97 2017-10-13 4 D 0 9375 5.21 D 2023-08-09 Common Stock 9375 0 D Non-Qualified Stock Option (right to buy) 4.52 2017-10-13 4 D 0 24792 6.66 D 2024-03-14 Common Stock 24792 0 D Incentive Stock Option (right to buy) 8.83 2017-10-13 4 D 0 39225 2.35 D 2025-03-16 Common Stock 39225 0 D Restricted Stock Unit 2017-10-13 4 M 0 6000 D Common Stock 6000 0 D Non-Qualified Stock Option (right to buy) 8.83 2017-10-13 4 D 0 44775 2.35 D 2025-03-16 Common Stock 44775 0 D Restricted Stock Unit 2017-10-13 4 M 0 25000 D Common Stock 25000 0 D Incentive Stock Option (right to buy) 9.12 2017-10-13 4 D 0 11131 2.06 D 2026-03-15 Common Stock 11131 0 D Non-Qualified Stock Option (right to buy) 9.12 2017-10-13 4 D 0 72869 2.06 D 2026-03-15 Common Stock 72869 0 D Restricted Stock Unit 2017-10-13 4 M 0 9000 D Common Stock 9000 0 D Restricted Stock Unit 2017-10-13 4 M 0 12000 D Common Stock 12000 0 D Incentive Stock Option (right to buy) 9.65 2017-10-13 4 D 0 10651 1.53 D 2027-03-08 Common Stock 10651 0 D Non-Qualified Stock Option (right to buy) 9.65 2017-10-13 4 D 0 73349 1.53 D 2027-03-08 Common Stock 73349 0 D Each restricted stock unit represented a contingent right to receive one share of SCLN common stock upon settlement. Shares of SCLN common stock received in settlement of performance rights not constituting derivative securities. Granted under Issuer's 2005 Equity Incentive Plan. Under its terms the option became exercisable in installments with 25% vesting on August 9, 2014 and 2.0833% vesting each month thereafter until it became vested in full on August 9, 2017. The option was canceled immediately prior to the merger of Issuer and Silver Delaware Investment Limited (the "Merger") in exchange for a cash payment per share from the Issuer in an amount equal to the excess of $11.18 per share over the exercise price. Under its terms the option became exercisable in installments with 25% vesting on March 14, 2014 and 2.0833% vesting each month thereafter until it became vested in full on March 15, 2017. Under its terms the option became exercisable in installments with 25% vesting on March 16, 2016 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger. Restricted stock units became fully vested and entitled to settlement immediately prior to the Merger and terminated upon settlement in shares of SCLN common stock. Under its terms the option became exercisable in installments with 25% vesting on March 15, 2017 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger. Under its terms the option became exercisable in installments with 25% vesting on March 8, 2018 and 2.0833% vesting each month thereafter until it became vested in full immediately prior to the Merger. Granted under Issuer's 2015 Equity Incentive Plan. /s/ Wilson W. Cheung 2017-10-16